ADC Therapeutics SA (ADCT) SEC filings

ADCTNYSEPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 4/30

$1.34−0.07 (-4.96%)

Close on Nov 13, 2026Market cap $171.08MP/E –Yield –

SEC filings

40 of ADC Therapeutics's most recent filings on SEC EDGAR

Document	Form	Period	Filed	Source
Quarterly report	10-Q	Sep 30, 2026	Nov 9, 2026	SEC EDGAR
Current report	8-K	Nov 9, 2026	Nov 9, 2026	SEC EDGAR
Current report	8-K	Nov 4, 2026	Nov 4, 2026	SEC EDGAR
Current report	8-K	Oct 7, 2026	Oct 13, 2026	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2026	Aug 13, 2026	SEC EDGAR
Current report	8-K	Aug 13, 2026	Aug 13, 2026	SEC EDGAR
Current report	8-K	Jun 30, 2026	Jul 2, 2026	SEC EDGAR
Current report	8-K	Jun 24, 2026	Jun 24, 2026	SEC EDGAR
Current report	8-K	Jun 3, 2026	Jun 3, 2026	SEC EDGAR
Current report	8-K	Jun 1, 2026	Jun 2, 2026	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2026	May 4, 2026	SEC EDGAR
Current report	8-K	May 4, 2026	May 4, 2026	SEC EDGAR
Proxy statement	DEF 14A	Jun 1, 2026	Apr 20, 2026	SEC EDGAR
Annual report	10-K	Dec 31, 2025	Mar 10, 2026	SEC EDGAR
Current report	8-K	Mar 10, 2026	Mar 10, 2026	SEC EDGAR
Current report	8-K	Feb 18, 2026	Feb 23, 2026	SEC EDGAR
Current report	8-K	Jan 12, 2026	Jan 12, 2026	SEC EDGAR
Current report	8-K	Jan 8, 2026	Jan 8, 2026	SEC EDGAR
Current report	8-K	Dec 3, 2025	Dec 5, 2025	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2025	Nov 10, 2025	SEC EDGAR
Current report	8-K	Nov 10, 2025	Nov 10, 2025	SEC EDGAR
Current report	8-K	Oct 12, 2025	Oct 14, 2025	SEC EDGAR
Current report	8-K	Sep 30, 2025	Sep 30, 2025	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2025	Aug 12, 2025	SEC EDGAR
Current report	8-K	Aug 12, 2025	Aug 12, 2025	SEC EDGAR
Current report	8-K	Jun 11, 2025	Jun 12, 2025	SEC EDGAR
Current report	8-K	Jun 3, 2025	Jun 5, 2025	SEC EDGAR
Quarterly report	10-Q	Mar 31, 2025	May 14, 2025	SEC EDGAR
Current report	8-K	May 14, 2025	May 14, 2025	SEC EDGAR
Proxy statement	DEF 14A	Jun 3, 2025	Apr 21, 2025	SEC EDGAR
Annual report	10-K	Dec 31, 2024	Mar 27, 2025	SEC EDGAR
Current report	8-K	Mar 27, 2025	Mar 27, 2025	SEC EDGAR
Current report	8-K	Jan 13, 2025	Jan 13, 2025	SEC EDGAR
Current report	8-K	Nov 11, 2024	Nov 13, 2024	SEC EDGAR
Quarterly report	10-Q	Sep 30, 2024	Nov 7, 2024	SEC EDGAR
Current report	8-K	Nov 7, 2024	Nov 7, 2024	SEC EDGAR
Proxy statement	DEF 14A	Nov 11, 2024	Sep 23, 2024	SEC EDGAR
Quarterly report	10-Q	Jun 30, 2024	Aug 6, 2024	SEC EDGAR
Current report	8-K	Aug 6, 2024	Aug 6, 2024	SEC EDGAR
Current report	8-K	Jun 13, 2024	Jun 14, 2024	SEC EDGAR

Where these numbers come from

Parsed from the XBRL in ADC Therapeutics's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is ADCT.

Compare: ADCT vs KURA · ADCT vs RCUS · ADCT vs ZYME · ADCT vs VSTM · ADCT vs BCYC

Revenue growth12.8% · median 97.8%

Operating margin-97.7% · median -193.7%

Net margin-95.7% · median -178.4%

Company	Revenue	Growth
ZYME	$265.97M	+97.8%
VSTM	$100.30M	–
RCUS	$100.00M	-58.3%
ADCT	$84.87M	+12.8%
BCYC	$83.53M	+194.7%
KURA	$79.31M	–

Company

Next earnings (est.): Mar 9, 2027, before open
Exchange: NYSE
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 188
Held by institutions: 72.9%
Auditor: PricewaterhouseCoopers SA
SEC CIK: 1771910

Advertisement
300 × 250

See a number that looks wrong?